Fungard

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Fungard
• 英文别名: [5-[2-[3-(3-amino-1-hydroxy-3-oxopropyl)-11,20,21,25-tetrahydroxy-15-(1-hydroxyethyl)-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[5-(4-pentoxyphenyl)-1,2-oxazol-3-yl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl] hydrogen sulfate
• 化学式: C₅₆H₇₁N₉O₂₃S
• 分子量: 1270.3
• InChiKey: PIEUQSKUWLMALL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  89
• 可旋转键数：
  18
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  519
• 氢给体数：
  16
• 氢受体数：
  24

ADMET

毒理性

• 在妊娠和哺乳期间的影响

哺乳期使用总结：目前没有关于哺乳期间使用米卡芬净的信息。由于米卡芬净大于99%与血浆蛋白结合，并且口服生物利用度低，它不太可能进入乳汁并被婴儿吸收。米卡芬净可以安全地静脉注射给4个月以下的婴儿。从乳汁中吸收的任何量都可能远低于婴儿剂量。如果母亲需要米卡芬净，这不是停止哺乳的理由。 ◉ 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 ◉ 对泌乳和乳汁的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:No information is available on the use of micafungin during breastfeeding. Because micafungin is >99% bound to plasma proteins and has poor oral bioavailability, it is unlikely to reach the milk and be absorbed by the infant. Micafungin can safely be given intravenously to infants under 4 months of age. Any amount absorbed from milk is likely to be far less than an infant dose. If micafungin is required by the mother, it is not a reason to discontinue breastfeeding. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

文献信息

• PREPARATION OF MICAFUNGIN INTERMEDIATES
  申请人：Barth Roland

  公开号：US20140329989A1

  公开（公告）日：2014-11-06

  The present invention relates to the preparation of compounds, in particular to the preparation of compounds of formula (I), which may be used with a compound of formula (VI), or a salt thereof as intermediates for the preparation of antifungal agents, preferably micafungin (MICA) or a salt thereof.

  本发明涉及化合物的制备，特别是涉及制备式(I)的化合物，该化合物可与式(VI)的化合物或其盐一起用作制备抗真菌剂，优选是米卡宁（MICA）或其盐的中间体。
• METHODS FOR MANUFACTURING AN ANTIFUNGAL AGENT
  申请人：Gunnes Solvi

  公开号：US20140371422A1

  公开（公告）日：2014-12-18

  The present invention relates to an improved process for the preparation of Micafungin.

  本发明涉及一种改进的米卡芬净制备工艺。
• METHOD FOR PURIFICATION OF MICAFUNGIN
  申请人：Xellia Pharmaceuticals ApS

  公开号：EP2699327B1

  公开（公告）日：2015-07-01
• NOUVEAUX MEDICAMENTS CYTOPROTECTEURS
  申请人：Balmes Transplantation

  公开号：EP3710038A1

  公开（公告）日：2020-09-23
• NOVEL CYTOPROTECTIVE DRUGS
  申请人：BALMES TRANSPLANTATION

  公开号：US20200397854A1

  公开（公告）日：2020-12-24

  The invention relates to compounds of the echinocandin family or a semi-synthetic derivative thereof or a salt thereof or an ester thereof, or an ester salt thereof, intended to be used as a cytoprotective drug, particularly as a drug for the prevention and/or protection and/or treatment of cell death and/or of degenerative pathological situations or processes which result in cell death, and even more particularly as a drug for the prevention and/or protection and/or treatment of cell death and/or degenerative pathological situations or processes which result in cell death, when they are associated with ischaemia-reperfusion.